Biohit Oyj - Financial Calendar

BIOHIT OYJ'S FINANCIAL INFORMATION IN 2011

Biohit Oyj will publish its Financial Statements for 2010 on Tuesday 1 March
2011 at 9:30 am. 

The Annual General Meeting of Biohit Oyj is planned to be held on Wednesday 13
April 2011 at 3 pm. The meeting will be convened later on by the Board of
Directors. 

The company will publish three interim reports in 2011 as follows:

  --  Interim Report January-March 2011 on Thursday 28 April 2011 at 9:30 am
  --  Interim Report January-June 2011 on Thursday 18 August 2011 at 9:30 am
  --  Interim Report January-September 2011 on Thursday 20 October 2011 at 9:30
      am

The reports and other stock exchange releases can be read online via Biohit's
website at www.biohit.com/investors. They can also be ordered to email through
the form at the same site. 

Biohit Oyj
Jussi Heiniö
President & CEO



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com



Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com



About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 400 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com